Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

General Health

Pharmaceutical

Cardiology

Biotechnology

Sirius Therapeutics

More Like This

Sirius Therapeutics to Present Data from Its Phase 1 Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders at the 66th ASH Annual Meeting and Exposition

Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders

Sirius Therapeutics Announces Submission to Begin First Clinical Trial of Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

PR Newswire associated0

ISTH announces launch of new global education initiative in factor XI/XIa inhibition

PR Newswire associated0

Seragon Completes Pre-Clinical Study of Aging Intervention Candidate SRN-901

Silence Therapeutics Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients